ClinicalTrials.gg
RecruitingNCT04351698SMILESUpdated Nov 1, 2023

SMILES: Study of Montelukast in Sickle Cell Disease

A Phase 2/3 interventional study of Montelukast and Oral Placebo in Anemia, Sickle Cell and Sleep-Disordered Breathing, sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 3 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
3 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 76 studies in Anemia, Sickle Cell with a site in United Kingdom — 14 open to participants now, 22 under way, 11 of them phase 3. Anemia, Sickle Cell · United Kingdom.

Planned enrollment
15th of 67
200 · median 88
Started
2023
with 6 others
Phase 2/3
4 of 76
2 open now
Primary completion
2024-09
later than 4 of 21 live
Registered
43rd of 76
by date

Among the 76 studies in Anemia, Sickle Cell with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2023, is one of 4 in phase 2/3, reaches primary completion later than 4 of the 21 other live ones, and was the 43rd registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

14 of the 76 studies in Anemia, Sickle Cell with a site in United Kingdom are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 3 Years to 8 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Anemia, Sickle Cell with a site in United Kingdom, or all of them as a file.
02

Study summary

Sickle cell disease (SCD) is a genetic blood condition causing long term health problems including pain and brain problems which affect quality of life. These may be made worse if patients have low night-time oxygen levels when the upper airways close repeatedly during the night (obstructive sleep apnoea). This is associated with increased pain, poorer concentration and increased kidney problems. Montelukast, widely used in the treatment of Asthma, has been shown to improve symptoms of obstructive sleep apnoea in patients without sickle cell anaemia. Investigators think this treatment could be useful in patients with sickle cell disease too. Early intervention with Montelukast could help prevent deterioration in concentration and thinking skills.

The aim of this trial is to see whether young children with sickle cell disease randomised (randomise: the same as tossing a coin and not knowing whether it will come up heads or tails) to Montelukast treatment have better thinking skills compared with people randomised to placebo (tablet with no active medical ingredients - i.e. "sugar pill"). This means that the child could be on Montelukast treatment or he/she might be on placebo tablets.

Read the detailed description

This trial, funded by Action Medical Research, will involve 200 SCD patients recruited from haematology clinics and ENT (ear, nose and throat) surgery waiting lists or their local sleep laboratory at Evelina Children's hospital (Guy's \& St Thomas), University College London hospital, North Middlesex hospital and Whittington Hospitals. Patients are eligible if they are between 3 and \<8 years old w SCD, give informed consent, have any Sleep-Disordered Breathing, e.g. snoring, and/or any abnormality on overnight oximetry. After consenting, the PI/Coordinator will organise a simple app-based questionnaire and baseline testing of brain speed, with an optional brain scan, and randomisation to chewable Montelukast tablets or Placebo for 3 months after which the brain speed tests, questionnaires and MRI will be repeated.

Purpose and design:

This is designed as a phase 2/3 trial of Montelukast therapy to investigate whether this drug improves processing speed, which appears to underpin the difference in full scale IQ (intelligence quotient) United Kingdom.

between children with sickle cell disease and their siblings.

Recruitment:

Patients will be recruited from the paediatric and adult sickle clinics at the involved hospitals. These clinics are attended by over 2000 patients with sickle cell disease.

This is a paediatric trial in a group of children who mainly belong to an ethnic minority as it is this age group who are vulnerable to sleep-disordered breathing (90% of children with sickle cell disease in our previous study snored). The investigators have successfully run 4 previous randomised controlled trials and 2 longitudinal studies in this group of children. The proposal has been developed by a multidisciplinary team of researchers/scientists, many of whom have lengthy clinical experience in this area. This team includes two patient representatives. Processing speed has been measured until recently using the Coding and Symbol search Wechsler subtests but investigators found that there was a practice effect in both arms of our pilot trial of continuous positive airways pressure, which was not seen for Cancellation, another test of processing speed and attention. The NIH toolbox processing speed is a new iPad test which has extensive normal data down to the age of 3 years, but a team member who has used it has found a practice effect. Investigators are therefore including 2 primary endpoints: Cancellation and the NIH toolbox processing speed It is possible that investigators will not recruit 200 patients across the 4 London sites so:

  1. Investigators have ensured that they will be adequately powered to detect an effect of Montelukast on adenoid: nasopharynx ratio on MRI if they recruit at least 3 willing to undergo MRI in each arm; this will allow exploration of the secondary brain MRI endpoints in addition to the primary endpoints.
  2. Investigators will extend to additional UK sites
  3. Investigators will apply for additional funds to extend the study outside the UK, e.g. by applying for $500,000 from the National Heart Lung and Blood Institutes (USA) to run the study in Cincinnati and New York.
03

Conditions studied

  • Anemia, Sickle Cell
  • Sleep-Disordered Breathing
04

Who can participate

Ages eligible
3 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 3 and \<8 years
  • with assent in accordance with institutional policies and European guidelines; ICF (informed consent form) must be signed by patients/guardian
  • HbSS 9homozygous SS disease) or HbSβ0 thalassaemia diagnosed by standard techniques (HPLC, IEF (Isoelectric focusing), MS (Mass spectrometry) or AlkE)
  • History of Sleep-Disordered Breathing, (i.e. parent-reported any degree of snoring (CHSQ questionnaire) and/or any abnormality on overnight oximetry compared with published data in children of the same age (e.g. nadir SO2 (oxygen saturation) \<93%; mean SO2\<96%))
  • Able to speak and understand English

Exclusion criteria

Exclusion Criteria:

  • Other neurodevelopmental disorders
  • Patient already on Montelukast
  • Patient has had side effects on or an adverse reaction to Montelukast in the past
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Investigation

    Montelukast

    Drug: Montelukast

  • Placebo comparator
    Match Placebo

    Matched Placebo

    Other: Oral Placebo

Interventions

  • Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.

    Also known as: singulair

  • OtherOral Placebo

    Inert chewable tablet with no therapeutic value

06

What researchers measure

Primary outcomes

  1. Change in processing speed scores from baseline to 12 weeks for participants with sickle cell disease randomised to the control arm or the treatment arm.

    NIH toolbox processing speed

    Time frame: 12 weeks

  2. Change in processing speed scores from baseline to 12 weeks for participants with sickle cell disease randomised to the control arm or the treatment arm.

    Cancellation (Wechsler scales and paper-and-pencil)

    Time frame: 12 weeks

Secondary outcomes

  1. Change in executive function (from NIH Toolbox® Cognition Battery) from baseline to 12 weeks for participants with sickle cell disease randomised to the control arm or the treatment arm.

    Dimensional Change Card Sort Test: There are 40 trials, and scoring was based on a combination of accuracy and reaction time. Flanker Inhibitory Control and Attention Test: There are 40 trials. For children aged 3-7.99 years scores of ≥ 90% using preliminary fish stimuli were followed that an additional 20 trials using arrows. Scoring was based on a combination of accuracy and reaction time. List Sorting Working Memory Test: The number of items in series increases from 2 to a maximum of 8. The test was discontinued when 2 trials at the same length were failed. Responses were entered by the examiner on a wireless keyboard. Children under 7 years did not complete this test. Scoring was based on the total number of items correctly recalled across all trials. Each measure will be analysed separately and as a combined composite. Higher scores indicate better executive function (mean = 100, standard deviation = 15, range = 50 - 150).

    Time frame: 12 weeks

  2. Change in executive function (parent reported questionnaire) from baseline to 12 weeks for participants with sickle cell disease randomised to the control arm or the treatment arm.

    Behavioral Rating Inventory of Executive Function (BRIEF-2) is an 63-item questionnaire that assesses EF behaviours in the school and home environments. The Global Executive Composite, Behavioural Regulation, and Emotion Regulation indices will be used in analyses. Higher T-scores (\> 65) indicate more clinical concern (range = 0 - 100).

    Time frame: 12 weeks

  3. Change in sleep and respiratory symptoms from baseline to 12 weeks for participants with sickle cell disease randomised to the control arm or the treatment arm.

    Children's Sleep Habit questionnaire (CSHQ): a 45-item parent-rated questionnaire that assesses the frequency of behaviors associated with common paediatric sleep difficulties (range = 0 - 135). Pediatric Sleep Questionnaire: a 22-item parent-rated questionnaire that asks about snoring frequency, loud snoring, observed apneas, difficulty breathing during sleep, daytime sleepiness, inattentive or hyperactive behaviour (range = 0 - 22). Total sleep time/total scores will be used in analyses. Higher scores are of greater clinical concern.

    Time frame: 12 weeks

  4. Change in pain symptoms from baseline to 12 weeks for participants with sickle cell disease randomised to the control arm or the treatment arm.

    Pain and hurt and pain management and control scales from the PedsQL - Sickle Cell Module: The PedsQL is a 43-item questionnaire with 9 dimensions that assesses health-related quality of life in individuals with SCD (pain and hurt range = 0 - 36, pain management and control range = 0 - 8). Total scores will be used in analyses. Lower scores are of greater concern.

    Time frame: 12 weeks

  5. Number of Participants With Treatment-Related Adverse Events from Montelukast

    All AEs (adverse events), hospital attendances, days of illness, and days lost from pre-school/school to be recorded on CRFs (case report forms) by coordinator and encrypted and stored separately

    Time frame: 12 weeks

  6. Change in Brain MRI from baseline to 12 weeks for participants with sickle cell disease randomised to the control arm or the treatment arm.

    Adenoidal size, volumetrics, white-matter integrity, structural and functional connectivity, perfusion) and nocturnal oximetry will be measured.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hood AM, Stotesbury H, Kolbel M, DeHaan M, Downes M, Kawadler JM, Sahota S, Dimitriou D, Inusa B, Wilkey O, Pelidis M, Trompeter S, Leigh A, Younis J, Drasar E, Chakravorty S, Rees DC, Height S, Lawson S, Gavlak J, Gupta A, Ridout D, Clark CA, Kirkham FJ. Study of montelukast in children with sickle cell disease (SMILES): a study protocol for a randomised controlled trial. Trials. 2021 Oct 10;22(1):690. doi: 10.1186/s13063-021-05626-6. PubMed 34629091 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Sep 2024, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2019
First posted
Apr 17, 2020
StartActual
Oct 16, 2023
Primary completionEst.
Sep 30, 2024
CompletionEst.
Sep 30, 2024
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04351698
Lead sponsor
Great Ormond Street Hospital for Children NHS Foundation Trust
Collaborators
Guy's and St Thomas' NHS Foundation Trust, University College London Hospitals, North Middlesex University Hospital, King's College Hospital NHS Trust, The Whittington Hospital NHS Trust
Responsible party
Sponsor
First posted
Apr 17, 2020
Start date
Oct 16, 2023
Primary completion
Sep 30, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Nov 1, 2023

Study contacts

Fenella Kirkham, MA MB Bchir
Contact
fenella.kirkham@ucl.ac.uk
+44 207 9052191
Satwinder Sahota, MSc
Contact
s.sahota@ucl.ac.uk
+442079052191
Fenella Kirkham, MA MB Bchir
principal investigator · University College, London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Montelukast

Start the discussion